Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 148-157

  Harris, Jules E ^a   Ryan, Louise ^a   Hoover Jr , Herbert C ^a   Stuart, Robert K ^a   Oken, Martin M ^a   Benson III, Al B ^a   Mansour, Edward ^a   Haller, Daniel G ^a   Manola, Judith ^a   Hanna Jr , Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR CELL VACCINE;

ADJUVANT THERAPY; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COLON CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; STATISTICAL ANALYSIS; SURVIVAL RATE; TUMOR CELL CULTURE;

EID: 0033985949     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.148     Document Type: Article

References (22)

1. Hanna MG Jr, Peters LC: Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer 42:2613-2625, 1978
2. Hanna MG Jr, Brandhorst JS, Peters LC: Active-specific immunotherapy of residual micrometastases: An evaluation of sources, doses and ratios of BCG with tumor cells. Cancer Immunol Immunother 7:160-173, 1979
3. Peters LC, Hanna MG Jr: Active-specific immunotherapy of established metastases: Effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. J Natl Cancer Inst 64:521-1525, 1980
4. Peters LC, Brandhorst JS, Hanna MG Jr: Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 39:1353-1360, 1979
5. Hoover HC Jr, Peters LC, Brandhorst JS, et al: Therapy of spontaneous metastases by an autologous tumor vaccine. J Surg Res 30:409-415, 1981
6. Hoover HC Jr, Surdyke MG, Dangel RB, et al: Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55:1236-1243, 1985
7. Hoover HC Jr, Brandhorst JS, Peters LC, et al: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-Year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390-399, 1993
8. Harris JE, Ryan L, Benson A, et al: Results of the ECOG trial of autologous colon carcinoma vaccine. J Immunother 14:358, 1993
9. Harris JE, Ryan L, Adams G, et al: Survival and relapse in adjuvant autologous tumor vaccine therapy for Dukes B and C colon cancer: EST 5283. Proc Am Soc Clin Oncol 13:295a, 1994 (abstr)
10. Hanna MG Jr, Key ME: Immunotherapy of metastases enhances subsequent chemotherapy. Science 217:367-369, 1982
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J Royal Stat Soc 135:185-206, 1972 (series A; with discussion)
13. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819-825, 1984
14. Hoover HC Jr, Surdyke M, Dangel RB, et al: Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. Cancer Res 44:1671-1676, 1984
15. Bystryn JC, Oratz R, Harris MN, et al: Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 61:1065-1070, 1988
16. McCune CS, O'Donnell RW, Marquis DM, et al: Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 32:62-66, 1990
17. Adler A, Gillon G, Hedwig L, et al: Active specific immunotherapy of renal cell carcinoma patients: A prospective randomized study of hormono-immuno-versus hormonotherapy - Preliminary report of immunological and clinical aspects. Biol Res Mod 6:610-624, 1987
18. Berd D, Maguire HC Jr, McCue P, et al: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. Clin Oncol 8:1858-1867, 1990
19. Restifo NP, Sznol M: Cancer vaccines, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 3023-3044
20. Hsu FJ, Caspar CB, Czerwinski D, et al: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129-3135, 1997
21. Morton DL, Foshag LJ, Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
22. Vermorken JB, Claessen AM, van Tinteren H, et al: Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 353:345-350, 1999